Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vostok New Ventures Ltd in connection with its in kind acquisition of BlaBlaCar
Mandate

Vinge advises Vostok New Ventures Ltd in connection with its in kind acquisition of BlaBlaCar

November 30, 2016

Vinge has advised Vostok New Ventures Ltd (”Vostok”) in connection with an investment in the Paris based ride-sharing service Comuto SA (”BlaBlaCar”).

The acquisition was made by an issue in kind where the purchase price for the shares in BlaBlaCar consisted of 4,154,495 newly issued shares in Vostok. A prospectus for listing of the Swedish depository receipts representing the issued shares was approved by the Swedish Financial Supervisory Authority and made public on 23 November, 2016. The Swedish depository receipts were admitted to trading on Nasdaq Stockholm on 25 November 2016.

Vostok is an investment company with a special focus on online marketplaces and businesses with strong network effects. As of 30 September 2016, the net asset value of the group was USD 632.44 million. The Swedish depository receipts of Vostok are listed on Nasdaq Stockholm, Mid Cap segment.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson, Frida Bäckegren, Joel Wahlberg and Sara Osman.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024